Progressive Elaboration Framework of Mortality Outcomes in Controlled Hypertension: A Qualitative Evidence Synthesis Systematic Review and Individual Participant Data Meta-Analysis 1
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,547
- 试验地点
- 1
- 主要终点
- All-cause vascular mortality
研究概览
简要总结
This review focuses on the assumption of mortality outcome of participants remaining label hypertension care is adequately managed when pressure targets are met with both qualitative and quantitaive method.
详细描述
For systematically review and synthesize the literature on main 2 questions
- Why do mortality outcomes still occur despite intervention of high blood pressure?
- What is the framework of high blood pressure death?
For Individual Participant Data Meta-analysis will be attracted from final analysis articles from the framework of data selection process only, the effect measurement and multi-variable model meta-analysis will be performed.
Sub-group analysis effect measurement following;
- Types and causes of death in patients with well-controlled hypertension.
- Underlying evidence or proposed mechanisms, biological markers, or comorbid conditions contribute to death despite optimal treatment.
- Treatment-related limitations, co-factors, and syndromes leading to uncontrolled fatal outcomes.
- Analyze possible mechanisms of cardiovascular death in controllable even intensive blood pressure control participants.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 1 Minute 至 130 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion:
- •Human birth in all sex chromosomes.
- •Study reports evidence of living with owned systemic/arterial hypertension by one of definition following;
- •Quantitative: Blood pressure number higher over the normal range by each protocol in mmHg unit in any arm of study.
- •Qualitative: Clarify the underwent both retrospective, observation or intervention of blood pressure and clearly clarify number of hypertension participants in article.
- •Study design: any type of studies and have a doi number.
- •In case report type study, the article recruit in only high blood pressure is a burden that reports both direct intervention for blood pressure or indirect intervention such as treatment of vascular damage from high blood pressure.
- •In a group of literature review type study, the number of hypertension participants with references from both in supplementary document or traced back via each doi number have to clearly declare in that free full-text and currently non-retracted article without personal requirement as raw material to processing the individual participant data meta-analysis
- •Study recruit only last version of study series that have to confirm published the hypertension participant with mortality outcomes.
- •English-language studies.
排除标准
- •Non human/human-specimen studies.
- •Evidence confirms local site or specific system hypertension only such as studies of pulmonary hypertension, portal hypertension, ocular hypertension without clearly defining the number of systemic arterial hypertension in articles.
- •No report of conclusion of participant such as no mortality report, no failed/successful outcome from last follow up from hypertension associated life-threatening event.
- •Deaths due to suicide, trauma, or illegal drugs including intend to take medication overdose in any reason.
- •Book, Testimonial, Interview, Conference, Protocol articles.
- •Sub-group analysis.
- •Duplicate one of the doi/nct/prospero numbers.
- •No doi. Number
研究组 & 干预措施
Mortality outcomes
Mortality outcomes or casue which mainly suspected from hypertension
结局指标
主要结局
All-cause vascular mortality
时间窗: Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years
Cardiovascular mortality (Cardiac-related death in controlled hypertension patients), cerebrovascular death(Stroke-related fatal outcomes in BP-controlled patients), renal occlusion/rupture/failure causing death (Mortality from renal failure in treated, controlled hypertensives), life-threatening vascular rupture, Major Adverse Cardiovascular Death or
次要结局
- Sudden death(Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years)
- End-organ failure leading to death(90 days outcomes after participant recruitment (death/alive))
- ICU death(90 days outcomes start with day 1 admit at ICU (death/alive))
- Maternal associated hypertension death(During pregnancy period from GA 1 week to delivery (pre-term, term-post-term) to 6 week follow up postpartum)
- Hypertension associated death in the young(Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 18 years of ages of participant)
研究者
Nathaphong Dejthida
Principle Investigator
DejthidaNathaphong